What is the significance of del(7q) in 96% of cells

TL;DR

Del(7q) in 96% of your cells means the deletion is present in almost all of your bone marrow cells, which is a significant finding that affects how your MDS is classified and treated — this is something your transplant team needs to address urgently.

---

KEY POINTS

• Del(7q) is a high-risk cytogenetic abnormality — it's associated with more aggressive MDS and higher risk of progression to acute myeloid leukemia (AML)
• 96% prevalence means this is the dominant clone — nearly all your bone marrow cells carry this deletion, indicating it's the primary disease population
• This finding changes your risk stratification — del(7q) typically places you in the higher-risk category according to NCCN and IPSS-R scoring systems
• Post-transplant relapse with del(7q) is a serious concern — your mixed donor chimerism status combined with del(7q) recurrence suggests possible disease recurrence rather than stable engraftment
• Urgent discussion with your transplant oncologist is critical — this may require treatment intensification or clinical trial evaluation

---

NEXT STEP

Contact your transplant team immediately to discuss these results and whether you need intervention such as donor lymphocyte infusion (DLI), hypomethylating agents, or clinical trial enrollment.

---

FULL ANSWER

Understanding Del(7q) in Your MDS

You've asked an important question about a significant finding in your genomic testing. Let me break down what del(7q) means and why the 96% prevalence matters for your specific situation.

What Is Del(7q)?

Del(7q) refers to a deletion of the long arm (q) of chromosome 7 — meaning a segment of genetic material is missing from this chromosome. This is one of the most well-studied cytogenetic abnormalities in myelodysplastic syndrome.

According to NCCN Guidelines for Myelodysplastic Syndromes, del(7q) is classified as a high-risk cytogenetic abnormality. This means:

• It's associated with more aggressive disease behavior
• It correlates with higher risk of progression to acute myeloid leukemia (AML)
• It typically indicates a worse prognosis compared to lower-risk MDS

Why 96% Prevalence Is Significant

The fact that del(7q) is present in 96% of your cells is critically important:

This indicates a dominant clone. A "clone" is a population of cells that all descended from a single abnormal cell. When 96% of your bone marrow cells carry the same deletion, it means:

• This abnormal cell population has become the overwhelming majority of your bone marrow
• The deletion is not a minor finding — it's the primary disease
• This level of clonal dominance suggests the del(7q) clone has a significant growth advantage

Comparison to lower percentages: If del(7q) were present in only 10-20% of cells, it might represent a smaller subclone. At 96%, it's the dominant disease population.

Del(7q) and Your Post-Transplant Status

Your medical profile shows you're post-allogeneic hematopoietic stem cell transplant (HSCT) with mixed donor chimerism — meaning your bone marrow contains both donor cells and your own cells. The presence of del(7q) at 96% in this context raises important questions:

Possible relapse: According to NCCN MDS Guidelines, the reappearance of cytogenetic abnormalities like del(7q) after transplant can indicate:

• Disease recurrence (relapse of your original MDS)
• Expansion of residual disease that wasn't completely eradicated by the transplant
• Loss of the graft-versus-leukemia (GVL) effect, where donor immune cells were controlling the disease

Your CD34 findings support this concern: Your results show "CD34 0% donor cells," which means the donor-derived hematopoietic stem cells (the cells that should be repopulating your bone marrow) are not present or are extremely low. This is abnormal in the post-transplant setting and suggests:

• Possible graft failure or graft loss
• The cells being produced may be from your own (recipient) cells, which carry the del(7q)

Risk Stratification and Prognosis

According to the NCCN Myelodysplastic Syndromes Guidelines and the Revised International Prognostic Scoring System (IPSS-R):

• Del(7q) alone is classified as a very high-risk cytogenetic abnormality
• When combined with refractory cytopenia with multilineage dysplasia (RCMD) — which is your diagnosis — this places you in a higher-risk MDS category
• The median overall survival for patients with del(7q) MDS is typically 12-24 months without intervention, though this varies based on other factors

However, your transplant status changes this picture. Post-transplant outcomes depend on:

• Whether this represents true relapse vs. mixed chimerism with disease control
• Your response to potential interventions
• Your overall fitness for additional treatment

What This Means for Your Treatment

The presence of del(7q) at 96% post-transplant typically triggers consideration of:

1. Donor Lymphocyte Infusion (DLI) — infusing more immune cells from your donor to boost the graft-versus-leukemia effect
2. Hypomethylating agents (azacitidine or decitabine) — these can be used post-transplant to control disease
3. Clinical trials — there are ongoing trials for post-transplant MDS relapse
4. Second transplant — in selected cases, if you're fit enough
5. Venetoclax-based combinations — depending on your blast percentage and fitness

Important Context from Medical Literature

The American Society of Clinical Oncology (ASCO) and European LeukemiaNet (ELN) both recognize del(7q) as a marker requiring:

• Close monitoring post-transplant
• Rapid intervention if disease recurrence is detected
• Consideration of clinical trial enrollment

---

Questions to Ask Your Transplant Team

Given these findings, here are specific questions you should discuss with your oncologist:

1. "Does this 96% del(7q) represent a true relapse, or could this be mixed chimerism with disease control?" — Understanding the distinction is critical for treatment planning.

2. "What is my current blast percentage, and how does that affect my treatment options?" — This determines whether you're eligible for certain therapies.

3. "Am I a candidate for donor lymphocyte infusion (DLI), and if so, what's the timeline?" — DLI is often a first-line intervention for post-transplant relapse.

4. "Are there clinical trials available for post-transplant MDS relapse with del(7q)?" — Clinical trials may offer access to newer therapies.

5. "What is my prognosis with this finding, and what are my treatment options ranked by likelihood of benefit?" — You deserve a clear picture of your situation.

6. "How often should I be monitored, and what would trigger a change in my treatment plan?" — Understanding your monitoring schedule helps you stay proactive.

---

Sources

This information is based on:

• NCCN Clinical Practice Guidelines: Myelodysplastic Syndromes (most recent version)
• American Society of Clinical Oncology (ASCO) Guidelines for MDS
• European LeukemiaNet (ELN) Recommendations for MDS Management
• National Cancer Institute (NCI) MDS Information

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.